2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Syn Bio Defense
Conor Hale, 21, (Conor Hale, 10-6-2021, Fierce Biotech, Ginkgo Bioworks 'a hoax for the ages,' says activist short seller firm, https://www.fiercebiotech.com/medtech/ginkgo-bioworks-suffers-short-attack-firm-calling-it-a-hoax-for-ages, 6-30-2023) SCade
Calling its business model “hocus-pocus” and “a colossal scam,” activist short seller firm Scorpion Capital has stung Ginkgo Bioworks. The synthetic biology company went public less than a month ago through a $1.6 billion special purpose acquisition company deal, which bestowed upon it a $23 billion market cap. Though it has promised the ability to harness living organisms to produce a range of industrial and biopharmaceutical chemicals through genetic editing, Scorpion said Ginkgo’s methods differ little from decades-old practices used to engineer yeast strains to manufacture food flavorings, fragrances, drug ingredients and more. In addition, the short seller said the majority of the company’s current income is based on “a dubious shell game” made up of customers that Ginkgo itself helped create and invested in, sending its money on a round-trip journey back into Ginkgo’s accounts. In about an hour following the publication of Scorpion’s 175-page report, Ginkgo’s stock price dropped at least 20%, down to about $9.50 a share. The report includes statements from current and former Ginkgo employees as well as others at connected companies. Ginkgo is currently trading at about $10. “Based on interviews with its related-party ‘customers,’ we believe that at least half of Ginkgo’s reported foundry revenue is phantom—that is, noncash and pure accounting hocus-pocus,” Scorpion wrote in its report, calling it a "hoax for the ages." The firm said it spoke with a senior member of one of Ginkgo’s largest customers, linked to tens of millions of dollars in reported deferred revenue, who said it never paid Ginkgo cash for its R&D services and instead used “free credits” that were given following equity investments by Ginkgo and Viking Global Investors, one of Ginkgo’s largest backers.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Syn Bio Defense
Jo Zayner, 23, (Jo Zayner, Dr. Jo Zayner is a visionary biochemist and genetic designer. For over 15 years, they have pioneered work in the field of bioengineering, publishing a number of scientific papers on the topic. Jo received their PhD in Biophysics from the University of Chicago, winning several awards for their work on engineering proteins. They then spearheaded work on developing engineered microbes for Mars terraforming at NASA, eventually leaving to start The ODIN, a bioengineering company based in Austin, Texas that is working to make genetic engineering accessible to everyone. Zayner’s groundbreaking work in human genetic engineering and medicine has been the focus of many documentaries, including the Netflix documentary Unnatural Selection and the NYT documentary Gut Hack. They have been made fun of on Last Week Tonight with John Oliver and written about in media all over the world including The New York Times, The New Yorker, El País, Le Monde, Time, Scientific American and NPR, among others., Phd, 1-2-2023, The death of SynthBio companies and my other predictions for Biotech in 2023, https://amateurgods.substack.com/p/the-death-of-synthbio-companies-and, 6-30-2023) SCade
The difficult realities of in vivo CRISPR gene editing therapies set in and funding slows. CRISPR’s use in human cells has been going on for about a decade. And while we have been promised the world, the only real success CRISPR has had in therapeutics is with ex vivo editing. Taking patient cells and editing them outside the body and putting them back in. So called CAR-T cell therapy is the most well-known example of this. While there have been a number of attempts at in vivo editing, using CRISPR gene editing on cells inside a patient’s body, none have really worked out. To date, the best success has been a therapy for ATTR amyloidosis but even then the treatment doesn’t actually prevent progression of the disease despite gene editing successfully. This therapy had high hopes because it was a liver target and therapies tend to accumulate in the liver, giving them a higher likelihood of success. The other low hanging fruit is eye therapies because of the immune privileged nature of the eye. One of the three FDA approved non-CRISPR gene therapies targets the eye, Luxturna. CRISPR clinical trials for eye disease have not progressed, implying that results have been very limited. I’m not saying we will never see in vivo CRISPR therapies. Look at RNA, it took 20ish years to mature into an FDA approved medicine. From the outlook right now I imagine in vivo CRISPR therapies are on the same track.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Syn Bio Defense
Jo Zayner, 23, (Jo Zayner, Dr. Jo Zayner is a visionary biochemist and genetic designer. For over 15 years, they have pioneered work in the field of bioengineering, publishing a number of scientific papers on the topic. Jo received their PhD in Biophysics from the University of Chicago, winning several awards for their work on engineering proteins. They then spearheaded work on developing engineered microbes for Mars terraforming at NASA, eventually leaving to start The ODIN, a bioengineering company based in Austin, Texas that is working to make genetic engineering accessible to everyone. Zayner’s groundbreaking work in human genetic engineering and medicine has been the focus of many documentaries, including the Netflix documentary Unnatural Selection and the NYT documentary Gut Hack. They have been made fun of on Last Week Tonight with John Oliver and written about in media all over the world including The New York Times, The New Yorker, El País, Le Monde, Time, Scientific American and NPR, among others., Phd, 1-2-2023, The death of SynthBio companies and my other predictions for Biotech in 2023, https://amateurgods.substack.com/p/the-death-of-synthbio-companies-and, 6-30-2023) SCade
The death of the synthetic biology company and the rise of consumer biotech. I’ma be honest, I’ve been pushing on the consumer biotech thing before everyone else thought it was cool. Growth for a company in the consumer space can take advantage of modern marketing techniques and the network effects and virality on social media. At The ODIN we have always sold our genetic engineering kits directly to consumers. Until around 2018ish the only really consumer biotech companies were fake meat companies like Memphis Meats aka Upside Foods. Even then, they aren’t real consumer companies because none of them have actually ever brought a biotech product to the consumer market. However, in the past few years we have seen a pivot of many traditional “Synthetic Biology” companies to making consumer products. Amyris, Bolt Threads, Geltor and others have pivoted to the cosmetics and beauty market. We are starting to see the failure of the platform/foundry style synthetic biology business model because creating synthetic biology products period, much less ones that can generate revenue, is a toughy even for the big names likes Gingko Bioworks and Amyris. I imagine that's why Amyris shifted and is set to bring in over $150 million in 2022 from consumer products alone and have been growing around 100% year over year. Look for consumer biotech companies to get even hotter.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Military Readiness defense
Lentzos et al. 14 – Flippa, a Senior Lecturer in Science & International Security at the Department of War Studies and Co-Director of the Centre for Science and Security Studies (CSSS) at King’s College London. Catherine Jefferson, researcher in the Department of Social Science, Health, and Medicine at King’s College London. Claire Morris, a senior research fellow in the Department of Social Science, Health, and Medicine at King’s College London. “The myths (and realities) of synthetic bioweapons”, Bulletin of Atomic Scientists, , 09-18-2014
Even experts have a hard time enhancing disease pathogens. Some observers have also expressed concerns that synthetic biology could be used to enhance the virulence or increase the transmissibility of known pathogens, creating novel threat agents.
Mousepox and bird flu (H5N1) experiments are frequently cited to demonstrate how dangerous new pathogens could be designed. But assessments of this threat tend to overlook a salient fact: In both these experiments, the researchers did not actually design the pathogens. With respect to H5N1, researchers had indeed been trying to design an air-transmissible virus variant for some time, without success. The ferret experiment was set up as an alternative approach, to see whether natural mutations could generate an air-transmissible variant. The researchers had no influence on the specific mutations induced. In the mousepox experiment, researchers inserted the gene for interleukin-4 into the mousepox virus to induce infertility in mice and serve as an infectious contraceptive for pest control. The result—that the altered virus was lethal to mice—was unanticipated by the researchers. In other words, it was not planned.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Military Readiness defense
Adams 18 – Gordon, Professor of international relations, American University's School of International Service; distinguished fellow, Stimson Center. “The Military’s ‘Readiness’ Scam Worked Again”, Foreign Policy, , 02-15-2018
The Donald Trump administration’s defense budget request for fiscal year 2019 is out, less than a week after Congress cut an overall deal on spending levels for 2018 and 2019. Unlike the domestic spending part of the administration’s budget request, the defense numbers aren’t dead on arrival — in fact, the military can count on getting every cent. The congressional deal set new levels for defense, agreeing to $700 billion for national defense in 2018 and $716 billion in 2019. That’s nearly $165 billion more than the military had anticipated prior to this year. The United States is back to defense spending, in constant dollars, that is higher than the peak spending levels under Ronald Reagan. Only in 2010, at the height of the wars in Iraq and Afghanistan, was defense spending higher.
It’s worth thinking about why defense spending is about to explode. It’s not because of some revolutionary change in the global security environment — aside from those pesky North Koreans and their nukes, America has never been so secure. It’s not because the U.S. military’s effectiveness has declined; it remains the most powerful force in the world, highly capable and very ready.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Military Readiness defense
O’Hanlon 17 – Michael, Senior Fellow at the Brookings Institution. “Is the Pentagon Headed for a Military Readiness Crisis?”, National Interest, , 10-09-2017
Washington is abuzz with talk that the U.S. military is increasingly hollow, and that its readiness is in crisis. American military readiness, defined as the ability of individual units in the armed forces to execute their assigned missions promptly and competently, is indeed uneven today, with some serious problems. A Department of Defense that downsized by more than a third after the Cold War ended, then spent fifteen years at war, and most recently also endured the budgetary shenanigans of sequestration and recurrent continuing resolutions, has indeed been through a lot. All would agree that the United States has asked a great deal of its soldiers, sailors, Marines, airmen, airwomen and their families, as well as the U.S. Coast Guard over in the Department of Homeland Security.
But some of the current talk goes dangerously too far. If believed literally, then it could embolden U.S. enemies, suck resources that are also needed for military innovation and modernization to fix short-term readiness problems, and make taxpayers wonder why the Pentagon can’t manage its forces better on $600 billion a year (well above the Cold War average). Just as bad—or worse—it could convince lawmakers to fund a big defense buildup by cutting the State Department, Agency for International Development, and other equally crucial parts of the country’s foreign-policy toolkit, as President Trump has proposed. That would hurt diplomacy and development far more than it would help the armed forces, given the proportionate amounts of money involved for each in any such reallocation.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Military Readiness defense
Morgan 19 – Brandon, an active duty Army infantry officer. He commissioned from the United States Military Academy in May 2013. He served as an infantry weapons platoon leader in Iraq during Operation Inherent Resolve and deployed to Europe with 2nd ABCT, 1st ID, where he served as the Atlantic Resolve Mission Command Element Liaison to Lithuania. He now serves as the brigade battle captain. “FUTURE CAPABILITIES OR READINESS? IT’S TIME TO RETHINK THE ARMY’S PRIORITIES”, Modern War Institute, , 02-02-2019
The US Army has been the world’s most dominant ground combat force for decades. But it now faces an uncertain question as to whether it can retain that dominance in the decades to come. To do so, it must take a hard look at the service’s priorities. For years, the service’s top priority has been readiness. While that remains important, it now needs to drop to the number two spot on the Army’s priority list, replaced by something else: the future fight. Specifically, developing future capabilities, technologies, and concepts should be the Army’s number one priority. Without considering such a change, the Army’s continued ability to fight well today will come at the cost of its ability to fight supremely tomorrow.
Upon assuming the duties of US Army chief of staff in August 2015, Gen. Mark Milley announced that “readiness is the number one priority, and there is no other number one.” In short, he directed that funding for the current fight (i.e., training at home station, rotations at combat training centers, and unit equipment) would take precedence over developing the future Army (his number two priority) and taking care of troops (number three). This prioritization made sense given the state of the Army and the context of the time. In Europe, the Army had withdrawn all remaining armored forces and cased the colors of its remaining Europe-based Corps command just prior to the 2014 Russian intervention in eastern Ukraine and annexation of Crimea. At the same time, ISIS emerged as a force that pillaged its way through much of war-torn Syria and a weak Iraq. All the while, North Korea, Iran, and China continued to defy the international community on things ranging from weapons development to malicious cyber activity. Prioritizing readiness made sense at the time and given that context. But as Gen. Milley prepares to depart his post, his successor as chief of staff of the Army must consider a new context, the conditions of which argue for transitioning to capability development for the future fight as the number one priority.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
NBC 6/18/2009 NBC “Why High Healthcare Costs Hurt the Economy” http://www.nbcnews.com/id/31432157/ns/business-personal_finance/t/why-high-health-care-costs-hurt-economy/#.WV-4O4jytPZ
In pushing for health care reform, President Barack Obama has said problems with the current health care system are a big cause of our economic troubles. He's even called the system, with its spiraling costs and inconsistencies in the amount and quality of care people get, a "ticking time bomb" for the federal budget. Just how serious is the problem? How big a role does health care play in the nation's economy? Here are some questions and answers about the economic impact of health care. How big a part of the economy is health care? It accounts for about one-sixth of the entire economy — more than any other industry. Spending on health care totals about $2.5 trillion, 17.5 percent of our gross domestic product — a measure of the value of all goods and services produced in the United States. That's up from 13.8 percent of GDP in 2000 and 5.2 percent in 1960, when health spending totaled just $27.5 billion — barely 1 percent of today's level, according to the Kaiser Family Foundation, a nonpartisan health policy group. What's included in that spending? It covers money paid to health care providers — hospitals, outpatient centers, Veterans Affairs and other clinics, doctor and dentist practices, physical therapists, nursing homes, home health services and on-site care at places such as schools and work sites. Also included are retail sales of prescription and nonprescription drugs, premiums paid to health insurers, and revenues of makers of medical devices, surgical equipment and durable medical equipment such as eyeglasses, hearing aids and wheelchairs. It also counts out-of-pocket payments by consumers for health insurance premiums, deductibles and co-payments, along with costs not covered by insurance and "medical sundries" like heating pads. Why does Obama say the health care system must be fixed first to repair the economy, and is it true? It's absolutely correct, for a host of reasons, experts say. "Health care is the economy," and fixing it would free up money for other priorities, such as education and industrial innovation, said Meredith Rosenthal, a Harvard University professor of health economics and policy. The health care system is dysfunctional and full of waste — as much as 30 percent of all spending, she said. Unlike most other markets, consumers rarely know which doctors, drugs or treatments are best for them, don't price shop and, if they're insured, don't know the full cost of care. That all can lead to unnecessary spending. Kaiser's president, Drew Altman, said health care costs have become pocketbook issues for businesses and both insured and uninsured Americans. Kaiser's periodic polls on what consumers worry about find the cost of health care and insurance are equal with job security, gas prices and being able to pay the mortgage. "People make the link, not just the president," he said, adding that they're most concerned with how reform will affect them personally. How do health care costs drag on the economy? Growth in overall health care costs, including spending on the huge Medicare and Medicaid programs, is out of control, said Robert Laszewski, president of consultants Health Policy and Strategy Associates. That limits how much money the federal government and businesses have to invest in solving the energy problem, developing products that can be sold to other countries, creating technology that can bring medical breakthroughs, building infrastructure and more. How do rising health costs affect workers and businesses? Health insurance premiums have skyrocketed, making it ever-tougher for workers and employers to afford them. From 1999 through 2008, annual health insurance premiums jumped 119 percent, according to Kaiser data. The average family premium paid by workers rose from $1,543 to $3,354 a year, and employer payments per worker jumped from $4,247 to $9,325. During that span, worker earnings rose only 34 percent and overall inflation was just 29 percent. So worker income has barely kept pace with inflation, more of the paycheck is going to health costs, and there's less left over for things like vacations, dining out, home improvements or a new car — especially for low-wage workers and retirees. That represents a huge drag on the economic growth, considering that consumer spending powers about 70 percent of the economy. For employers, particularly small businesses, rising insurance premiums mean there's far less money for new equipment, better facilities, research or expansion. That means fewer new jobs, plus smaller raises and higher health premiums for workers, further limiting consumer spending. What's the impact of 50 million Americans having no insurance? Ira S. Loss, senior health care analyst at Washington Analysis, puts it this way: "We're paying to take care of those people." Hospitals, particularly in inner-city and rural areas, charge patients with insurance more to help make up for those who can't pay their bills. And we're all paying more in taxes to cover extra payments by federal and state governments to hospitals that have large shares of uninsured patients. Isn't health care one of the few parts of the economy that's growing? Yes. Employment in the huge health care sector has grown by about 427,000 jobs — nearly 3 percent — since the recession began in December 2007, and totaled 15.5 million jobs in April, the latest month for which U.S. Bureau of Labor Statistics figures were available. Most of the increases came in ambulatory care services (up 254,400 jobs) and hospitals (up 148,400 jobs). That was partly offset by job declines at pharmaceutical companies, drug wholesalers and pharmacies. However, only 42,900 jobs have been added since January. That's because the steady growth in jobs throughout the recession in ambulatory care, hospitals and, to a lesser extent, health insurers, has slowed dramatically over those months, with hospitals adding only 7,700 jobs and insurers just 1,000. Obama and Congress are trying to reduce the rate at which health care spending is growing, by eliminating waste and fraud, improving efficiency and increasing preventive care, so it's unlikely jobs at health care providers will decline. In fact, more caregivers will be needed for aging baby boomers, plus the millions who could get coverage under health care reform and presumably would seek care more regularly. So despite the system's faults, there's an economic silver lining: As Altman of the Kaiser Family Foundation explains, health care has been "one of the few engines of job growth during the recession."
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Largent 16 [Emily Largent graduated magna cum laude and Phi Beta Kappa from Georgetown University’s School of Foreign Service in 2004. She continued her education at the University of Pennsylvania’s School of Nursing, graduating summa cum laude in 2006, after which she worked as a cardiothoracic intensive care unit nurse. From 2008 to 2010, she was a fellow in the Department of Bioethics at the National Institutes of Health. In 2016, she received the PhD degree in Health Policy, with a focus in ethics, from Harvard’s Graduate School of Arts and Sciences and the JD degree cum laude from Harvard Law School. Her current research interests include the ethics of human subjects research, particularly offers of payment made to research participants and the ethics of conducting research in public health emergencies.] “EBOLA and FDA: reviewing the response to the 2014 outbreak, to find lessons for the future” Journal of Law and the Biosciences, 489–537 () - MZhu
The standard model, just outlined, has significant limitations in public health emergencies like the West African EVD outbreak. As just described, developing a new drug and getting FDA approval is time consuming. Companies may spend years—or even decades—developing a drug and ushering it through clinical trials before they send an NDA to FDA for review, which then takes 6 months or more. While this is true of all drugs, there are two key implications in a public health emergency. First, it is exceedingly unlikely that an entirely new treatment will or even can be developed from scratch during an epidemic. Rather, promising compounds must already be far along the development pipeline if they are to have an impact in the near term. EVD might be relatively unique among public health threats in that there had already been significant investment in basic research and drug development before the 2014 outbreak in light of concerns the Ebola virus might be used in bioterrorism. Promising compounds are unlikely to be at the ready if a public health emergency is the result of a NTD or comparable illness that is not commercially attractive to pharmaceutical companies or if it is the result of an emerging threat with which clinicians and researchers have yet to become familiar. Second, even if a drug has already been developed, including the completion of clinical trials, if it is not yet FDA approved, it is unlikely that FDA will be able to approve it in time to meet the most pressing patient demands in an outbreak. Taken together, these two considerations suggest that it is extremely important to prioritize drug development and approval of drugs addressing public health threats in interoutbreak periods to the greatest extent possible, granting that the ‘greatest extent possible’ might be quite limited. Further challenges to drug development, approval, and access arose in the 2014 outbreak and are likely to recur in future public health emergencies. First, as mentioned in Section II, it was necessary to conduct clinical trials in the midst of the outbreak because it is unethical intentionally to expose healthy research participants to the Ebola virus. Yet, conducting research in the midst of an outbreak raised contentious ethical and methodological questions, and people had widely divergent views on how best to proceed. Furthermore, conditions on the ground, discussed in Section I, made both the delivery of care and the conduct of research extremely difficult from a practical perspective.218 Although the particular challenges that will be confronted on the ground in any given public health emergency cannot be anticipated in advance, there are ethical, methodological, and practical considerations that can and should be anticipated and addressed as part of pre-planning for clinical trials that will transpire in such circumstances. Second, there were few doses of experimental interventions available for conducting clinical trials, and as the outbreak receded and the number of EVD cases waned, the epidemiological trajectory made it increasingly difficult to conduct RCTs, to show efficacy.219 Even if an experimental intervention had successfully passed through clinical trials, however, FDA and other regulatory agencies were likely to confront relatively limited data on safety and efficacy in light of the small size of the patient population. Thus, it is necessary to consider whether alternative approval pathways are appropriate, how data collection standards might be compromised in an epidemic to achieve the appropriate balance between speeding approval and protecting drug consumers, and what, if any, post-marketing trials should be required. Finally, the prospect of FDA approval raises important questions about who should have access to FDA-approved therapies in a public health emergency and how this will be accomplished. MSF, for example, worried that there was no mechanism to ensure that West African patients would have access to EVD treatments. An FDA-approved drug is of little value if it does not get into the hands of those who need it because, for example, they cannot afford it or because it cannot be manufactured in sufficient quantities. Although there are independent normative arguments for why global health inequalities should be addressed, in a public health emergency—particularly in an age when global air transit brings us together and exposes us more widely to health risks— there are additional self-interested reasons to ensure broad access.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Jeffrey Clemens, January 2014, Jeffrey Clemens is an assistant professor of economics at UC San Diego, " Health Reform and the Future of Medical Innovation ", Scholars Strategy Network, https://www.ifpma.org/insights/the-power-of-partnerships-and-innovation-accelerating-progress-toward-universal-health-coverage-by-2030/, 6-28-2023, //ms
Because advances in health care are at once so costly and so valuable, it is important to understand how the course of innovation may be influenced by new public policies – like the ongoing rollout of the 2010 Affordable Care Act. To understand what is at stake, I have looked at the Great Society reforms of 1965, which introduced Medicare coverage for the elderly and Medicaid coverage for the poor. My research shows that sustained increases in medical innovations followed these reforms. U.S. patents for medical equipment innovations increased by 40 percent, compared both to other U.S. patents and to foreign medical patents. Advances continued apace as Medicaid and private insurance became increasingly comprehensive during the 1970s and 1980s. But to decipher whether the Affordable Care Act is likely to have similar effects, we must dig more deeply into the processes by which medical innovations happen.
The Roots of Medical Innovation
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Nikhil Sahni, Anuraag Chigurupati, Bob Kocher, Mddavid M. Cutler, 10-13-2015, "How the U.S. Can Reduce Waste in Health Care Spending by $1 Trillion," Harvard Business Review, https://hbr.org/2015/10/how-the-u-s-can-reduce-waste-in-health-care-spending-by-1-trillion
During the presidential campaign, Americans will be bombarded with proposals to improve the U.S. health care system in ways big and small that would either build on or radically revamp the Affordable Care Act (ACA). All will claim to reduce costs and improve quality. In order to accomplish this, proposals will largely focus on what is termed “wasteful spending” in health care, spending not associated with improved quality that, by some estimates, accounts for over one-fourth of total health care spending. But, as Michael Porter and Robert Kaplan of Harvard Business School have argued, we need to examine costs at a more granular level at which clinical outcomes are matched with the business and administrative processes. While this has been challenging, experts have recently better measured the effectiveness of many interventions, ranging from demand-side options such as consumer-directed health plans to supply-side options such as alternative methods to pay care providers. These interventions are beneficial because they eliminate mostly waste in the system, avoiding the hard trade-offs among cost, quality, and access to care. To assess what we already know we can save in our system and where policymakers, entrepreneurs, investors, and health care leaders need to focus their attention, we categorized the interventions measured by experts into the different strategies put forth by various presidential candidates and analyzed their total potential savings. We reviewed four strategies: the current health care system’s trajectory as is; comprehensive demand-side reform; aggressive supply-side reform; and a combination of demand-side and supply-side reform. We had two key findings: The political rhetoric about demand-side versus supply-side as a better option is ill-founded; both have roughly the same effect on total spending. Even if the United States implemented all the approaches whose effectiveness has been measured, only 40% of the estimated $1 trillion of wasteful spending would be addressed, leaving a significant opportunity for innovation in all areas of health care. Before looking at what can and should be done, it’s important to note that the public and private sectors have already made significant strides in reducing the growth in health care costs and improving quality. As a result, the United States experienced five years of the lowest growth in health care costs ever in the 2009-2013 period — although an uptick in the rate in 2014 raises questions about what it will take to contain costs on a sustainable basis. Notably, the adoption of value-based-payment reforms in the private sector such as Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract coupled with public-sector reforms such as accountable care organizations and bundled-payment initiatives appear to be changing how the delivery system is organized and importantly makes money. There has also been progress in the implementation of demand-side measures aimed at getting consumers to make wiser purchasing choices. These include the widespread adoption of health plans like Silver plans on state exchanges that require subscribers to share at least 30% of the costs up to a specified limit and the introduction of technology to allow consumers to make informed decisions such as Castlight Health’s price-transparency tools. These trends likely result in market-share gains for providers that deliver high quality at lower costs. A collaboration of the editors of Harvard Business Review and the New England Journal of Medicine, exploring cutting-edge ways to improve quality and reduce waste. Tell us what health-care content you’d like to see more of from HBR. Take our survey and download “How Not to Cut Health Care Costs” as a thank you. While only 20% of health care expenditures flow through new value-based payment models and only 20% of people with employer-sponsored insurance are in high cost-sharing plans, both shares are expected to grow rapidly. The U.S. Department of Health and Human Services has stated that it plans to shift at least 50% of all its payments to these new payment models by 2018. Since provider margins are razor thin and fixed costs are very high, small changes in incentives or market share should have a significant impact. We believe that the current set of public- and private-sector activities will continue to work and generate annual savings of $140 billion (achieved over five years), representing approximately 5% of health care spending in 2014. To put this in perspective, the annual savings generated by these programs represents more than five times the average annual federal savings that the Congressional Budget Office estimates that the Affordable Care Act (ACA) will produce this decade. There are two primary ways to reduce costs and improve quality much more: a comprehensive demand-side strategy that gives consumers incentives and information to be much better purchasers of health care, and an aggressive supply-side strategy that changes the way providers are paid so their profit margins are tightly linked to outcomes and efficiency rather than the volume of services delivered. We believe that the United States should pursue both strategies. Specifically, policymakers could adopt the following reforms that have been proven to work: Comprehensive demand-side reforms. Accelerate the growth of consumer-directed health plans paired with other reforms to encourage consumers to be more sensitive to prices. These reforms should include increased regulations to promote price and quality transparency and payer innovations to introduce insurance plans with reference prices. With this strategy, the country could achieve an incremental $110 billion in savings beyond the $140 billion it’s already on the path to achieve, representing an additional 3% of health care spending. However, this approach would not be totally positive: Evidence suggests that some portion of the reduction in costs would result from the patients not seeking necessary care due to increased sensitivity to prices. Innovation in insurance products, such as value-based-insurance designs that reduce cost sharing for highly effective clinical services, can help address these concerns. Aggressive supply-side reforms. Accelerate the migration from the fee-for-service payment system to alternative payment methods such as bundled payments or capitated budgets for individuals, which will also drive providers to reorganize their care-delivery models. This strategy would save a similar amount to the demand-side strategy, and evidence from early implementations suggests it will result in no reductions in quality or the use of “necessary” care. The choice between demand-side and supply-side reforms is artificial. We can pursue both together. That would generate an incremental $170 billion in savings (rather than the $220 billion total of each) due to some overlap. By also pursuing other concrete opportunities (e.g., reducing administrative complexity to the levels in other service industries) that would yield $130 billion, the United States could save a total of $440 billion per year, or 14% of total spending on health care. If achieved over five years, this would halve the projected growth in health care spending, reducing the average annual growth rate from 5.5% to 2.4%. This, however, only represents 40% of the waste in the health care system, leaving another 60% of waste, or 20% of total health care spending, that could be eliminated. Of this remaining $600 billion-plus opportunity, wasteful clinical goods and services account for about a third, illegal fraud and abuse (bending the rules or not following good medical practices) for roughly another third, administrative complexity one-fifth, and excessive, or unjustifiably high, prices the remainder. Therefore, in addition to implementing everything that have been proven to work, the United States should create an environment that encourages innovations that can address areas of waste such as administrative complexity that known strategies cannot eliminate. Finding ways to address these challenges will help unleash unprecedented productivity increases in the health care system, extend the viability of the Medicare trust fund by years, allow employers to use money that would otherwise go to health care to raise wages, and, by reducing state and federal expenditures on health care, permit governments to lower taxes.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Eve Luppert, 2016 http://bigthink.com/articles/how-a-single-payer-health-care-system-can-drive-innovation-into-the-economy
A SINGLE-PAYER SYSTEM COULD DRIVE INNOVATION INTO THE NEW ECONOMY I've been an HR professional for the past 20 years. I have fought with insurance companies t1hrough most of that time. More recently I've seen the impact on people who have lost their jobs and for the first time are really having to face the outrageous cost of health insurance for the first time. I think there is a willingness and understanding of the benefits of a single payer system in the US for the first time. Many of us would very much like to give up the corporate life and start our own, new businesses, creating tomorrows jobs. We know a change in how we work and what we do is coming and we want to be at the forefront of it. However, the difficulty in keeping ourselves and our families protected from health care costs will inevitably drive many great people back into corporations where their great ideas will die a slow death. The naysayers to national health care threaten that we will have no "choices". But I believe that being forced to live the company life is not a choice that many who have been knocked out of their old jobs want to make.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Anamaria Lopez, 7-8-2017, Anamaria Lopez is a research intern at INET. She is currently studying economics at Columbia University, where she works as a research assistant in the offices of Anya Schiffrin and Joseph Stiglitz. Specific areas of interest include economic policy and media freedom in Latin America and the Global South. "The Economic Case for Single Payer Health Care in the US", Institute for New Economic Thinking, https://www.ineteconomics.org/perspectives/blog/the-economic-case-for-single-payer-health-care-in-the-us, 6-28-2023, //ms
Why the government should be the payer L. Randall Wray, Professor of Economics at Bard College in New York, criticizes the framing of single-payer health care as “universal health insurance.” Wray argues that a single-payer health care system would in reality need to operate very differently than a universal health insurance program—largely because the concept of covering health care through an insurance system in the same way that we cover our homes or cars is fundamentally flawed. He explains that going to the doctor is not like going to the auto repair shop: Humans require consistent, preventative health care, and for-profit insurance isn’t designed to provide it. Wray notes that home or auto insurance is designed to be a “bad deal” for consumers, who pay premiums throughout their lives to protect themselves in the rare event that their house catches on fire or they get into a high-impact car crash. Health care is different because coverage isn’t just about catastrophe: Most costs go toward routine or preventative care, like annual checkups. As Wray puts it, routine health care is “not analogous to an ‘act of God’ that destroys your house: It is predictable, welcome, and life-enhancing.” Economist Gerald Friedman, also of University of Massachusetts Amherst, has similar concerns about applying insurance companies’ profit-based business model to health care coverage. Such an arrangement leads to “adverse selection,” he says. Friedman explains that because of the concentration of health care spending on a few sick and injured individuals, private insurers will seek to save costs by identifying and avoiding such people— a practice called “lemon dropping”—while attracting the healthy—or “cherry picking.” Even with Obamacare protections around preexisting conditions, insurers are able to drop out of the Obamacare market altogether. While these strategies are profitable for insurers, they raise costs for consumers, putting those who can least afford to pay at risk. Like Baker, Friedman is also concerned with the soaring price of pharmaceuticals and hospital services in the U.S., and argues that only a single-payer system can reverse the trend: A system with multiple insurers leaves none with the market power to stand up to elite providers, including drug companies and hospitals. Gerald Friedman Over time, Friedman argues, a single-payer system will not only cut costs, but also significantly improve the quality of health care and lead to more innovation and deeper research. For example, there are currently no data on outcomes and health care utilization across the country other than those collected by the VA and Medicare. The mass of data a single-payer system would accumulate—across the population and over time—would open doors to more conclusive research and “allow for quality analysis of treatment and provider behavior,” says Friedman. In the long run, he says, such data—and the system that produces it—could revolutionize the way health care is practiced in the US.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Kesselheim et al 16 – Aaron S. Kesselheim, Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital, M.D. and J.D. from University of Pennsylvania School of Medicine and Law School, MPH from Harvard School of Public Health, primary care physician at the Phyllis Jen Center for Primary Care at Brigham & Women’s Hospital, Jerry Avorn, Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital, M.D. from Harvard Medical School in 1974, and completed a residency in internal medicine at the Beth Israel Hospital in Boston, Ameet Sarpatwari, PhD in epidemiology at the University of Cambridge, Instructor in Medicine at Harvard Medical School, an Associate Epidemiologist at Brigham and Women’s Hospital, and Assistant Director of the Program On Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics, JD at the University of Maryland as a John L. Thomas Leadership Scholar, Principal Investigator on a Greenwall Foundation Making a Difference in Real-World Bioethics Dilemmas grant and a Faculty Affiliate with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Behavioral Insights Group at the Harvard Kennedy School (“The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” Journal of the American Medical Association, Vol. 316, No. 8, pgs. 858–871, August 23rd, Available to Subscribing Institutions)
Justifications for High Drug Prices The pharmaceutical industry has maintained that high drug prices reflect the research and development costs a company incurred to develop the drug, are necessary to pay for future research costs to develop new drugs, or both. It is true that industry often makes expensive investments in drug development and commercialization, particularly through late-stage clinical trials, which can be costly.84 These assertions have been used to justify high prices on the grounds that if drug prices are constrained, the pipeline of new medications will be adversely affected. Some economic analyses favored by the pharmaceutical industry contend that it costs $2.6 billion to develop a new drug that makes it to market.85 However, the rigor of this widely cited number has been disputed.86,87 A number of factors weigh against these rationales for high drug prices. First, important innovation that leads to new drug products is often performed in academic institutions and supported by investment from public sources such as the National Institutes of Health. A recent analysis of the most transformative drugs of the last 25 years found that more than half of the 26 products or product classes identified had their origins in publicly funded research in such nonprofit centers.88 Other analyses have highlighted the importance of small companies, many funded by venture capital.89,90 These biotech startups frequently take early-stage drug development research that may have its origins in academic laboratories and continue it until the product and the company can be acquired by a large manufacturer, as occurred with sofosbuvir. Arguments in defense of maintaining high drug prices to protect the strength of the drug industry misstate its vulnerability. The biotechnology and pharmaceutical sectors have for years been among the very best-performing sectors in the US economy. The proportion of revenue of large pharmaceutical companies that is invested in research and development is just 10% to 20% (Table 4); if only innovative product development is considered, that proportion is considerably lower.91 The contention that high prescription drug spending in the United States is required to spur domestic innovation has not been borne out in several analyses.92 A more relevant policy opportunity would be to address the stringency of congressional funding for the National Institutes of Health, such that its budget has barely kept up with inflation for most of the last decade. Given the evidence of the central role played by publicly funded research in generating discoveries that lead to new therapeutic approaches, this is one obvious area of potential intervention to address concerns about threats to innovation in drug discovery. Thus, there is little evidence of an association between research and development costs and drug prices93; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear. This explanation also helps to account for several high-profile case studies, including high-priced new branded products94 and exorbitantly priced generic drugs described above.95 In preparation for recent hearings on this topic, the US House Committee on Oversight and Government Reform subpoenaed internal correspondence from Turing and Valeant Pharmaceuticals, which had sharply increased the prices of older drugs the companies had acquired. The investigation revealed, for example, that Turing received “no pushback from payors” when it increased “Chenodal price 5x... [Thiola] price 21x... [and Daraprim] price 43x.”96 Similarly, Gilead spent $11 billion to purchase sofosbuvir from Pharmasset, a small biotechnology firm that developed the drug, based in part on federally funded research led by an investigator at Emory University.97 Gilead recouped almost all of this cost in the first year that sofosbuvir was on the market, recording sales of $10.3 billion in 2014.98 In December 2015, the US Senate Committee on Finance released a detailed report based on its access to internal company documents on Gilead’s strategies to maximize the prices it could charge for both that drug and its planned successor, which the company also owned.99 In the current system for drug payment in the United States, few options exist to counter this approach. Companies should of course be rewarded fairly for the research innovations they make that help generate new drug products and for their costly trial work that facilitates the assessment and availability of new medications. But providing them with large incentives to do the opposite is counterproductive. Clinical Consequences of High Drug Prices The high cost of prescription drugs in the United States has clinical as well as economic consequences.100,101 Even though more Americans have drug coverage as a result of the Medicare drug benefit plan and the Patient Protection and Affordable Care Act, cost-containment strategies in recent years have shifted an increasing share of drug expenses to patients.102 Private insurers have increased deductibles103 and most co-payments, and added a new payment tier for certain specialty drugs in which patients must pay coinsurance—often between 20% and 33% of the total drug price—rather than a simple co-payment.104 Although such cost-shifting measures have helped “bend the cost curve” for employers and payers, they can reduce use of effective medications.105,106 Almost a quarter of 648 respondents to a 2015 poll reported that they or another family member did not fill a prescription in the last year because of cost.107 In other studies, patients who were prescribed a costly branded product rather than a more affordable generic alternative were found to adhere to their regimen less well than those receiving a similar generic drug12 and to have worse health outcomes.108 Nonadherence due to all causes has been estimated to contribute to $105 billion in avoidable health care costs annually.109 In some cases, manufacturers have attempted to circumvent higher co-payments by providing patients with coupons that reimburse their out-of-pocket expenses.110 Coupons can be useful for patients with no other option, but they leave the insurer obliged to pay the much larger amount of each prescription’s costs, thereby increasing health care spending. This approach has become common for branded drugs that have comparable but much less expensive alternatives.111 Faced with fixed health care budgets, states with higher drug costs for their Medicaid programs have had to reduce other services or increase health care eligibility requirements.112 Several state Medicaid programs, for example, have imposed nonevidence-based policies to restrict sofosbuvir, including denying coverage to users of alcohol or other drugs.113,114
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Ibrahim Ribery Sep 24, 2020 Debunking the Medicare For All Innovation Dilemma https://ribery-ibrahim72.medium.com/debunking-the-medicare-for-all-innovation-dilemma-29d276383108
Arguing that innovation decreases due to decreased drug prices with M4A are absurd. Clearly, in the Medicare For All Bill, the price of a drug will be based on the societal value of the drug and the uniqueness of the drug. This system (also known as Value-Based Pricing) will not decrease the prices of new innovative medicines which a majority of small businesses create instead; it would not allow the creation of copycat, Me-Too, drugs by large pharmaceutical monopolies. Medicare For All solves the problems of the low competition in the production of the drugs as the government will brunt the cost of buying these drugs instead of the people. In a Value-Based System, there are two possibilities of the future of innovation At Best- Pharmaceutical company’s revenues will increase on the net because of the optimization of the prices of the drugs. In simple terms, small Pharma companies will not be affected because they already create new medicines that don’t subject them to the ruling of Value-Based Pricing. But now they don’t have Big Pharma creating a copycat and redirecting the market away. And it will change the incentives of Big Pharma because they will be forced to develop innovative drugs rather than the copycats. At worst- Only the revenues of Big Pharma will decrease because they have to shift away from their current strategy. While this may be bad right now, in the long term, it is essential to switch big companies’ incentives to create disruptive innovation. Big companies are larger, have more staff, and are self-funded meaning they can create more drugs in a quicker time and without being dependent on private investors to create life-saving diseases. Given these two possible scenarios innovating in a single-payer market is bound to increase with big pharma and small pharma. New innovation is very important in times like this and to prevent future diseases from becoming out of hand. Rather than innovating one step behind the disease under Medicare For All we will always be one step ahead
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Jim Tananbaum is the founder and CEO of Foresite Capital, a San Francisco-based biotechnology investment firm. Pharma and biotech should embrace ‘Medicare for all,’ not defeat it Feb. 27, 2019 https://www.statnews.com/2019/02/27/pharma-biotech-embrace-medicare-for-all/
Without a greater government role in health insurance, many of the discoveries emerging from the labs of these industries will never reach patients. Why? Gene-based treatments that save someone from dying 20 years in the future have no chance of being embraced by private insurers whose business model depends on annual renewals. It doesn’t make sense for them to buy a costly, high-tech intervention that pays off years or even decades after its recipients stop paying premiums. This growing disconnect explains why genetic research will soon make Medicare for all, or something similar, all but inevitable. The time horizons for medicine on the one hand and employer-based health insurance on the other have simply moved too far apart. When employers began offering health insurance in the , jobs were expected to last a lifetime and nearly all treatments worked within weeks. Paying a modest sum to treat sick employees with penicillin or tetracycline, the technological wonders of the day, so they could return to the factory floor for another 20 years made obvious financial sense. Today, jobs in the gig economy last months or a few years, while medical interventions may take decades to bear fruit. How many employers view sparing a woman from breast cancer 20 years hence as a sound investment in their labor force? A new wave of genetic tests and treatments promises to make this disconnect an almost unbridgeable chasm. Fifteen years after the sequencing of the human genome, pharmaceutical and biotechnology companies are poised to offer cures for a host of deadly genetic abnormalities, including and . Beyond these highly targeted treatments, scientists are uncovering genetic patterns that place at higher risk of heart attack, stroke, cancer, and other serious diseases. Patients and their doctors will soon be faced with myriad decisions about the tests and treatments needed to stave off potentially life-threatening events that may not manifest themselves for decades. But prices for some new treatments already and will likely soon . The justification for such eye-popping sums is that the interventions offer patients decades of new or disability-free life. And in a newly interconnected health care system, the treatments could substitute for less-targeted but equally expensive care options, saving money over the long term. These are the great promises of precision medicine and value-based health care. But the key idea here is “long term,” a time period that neither employers nor insurers are interested in anymore. Nowadays, only governments have the financial and political wherewithal to invest in keeping people as productive and taxpaying members of society over their lifetimes. To be sure, insurers have long paid for preventive interventions like measles vaccines, cholesterol-lowering drugs, and annual checkups. But many of these are modest measures intended to prevent catastrophic events in the near future. Genetic screening will vastly expand not only the range of diseases targeted but the time period for preventing them. Insurers, devoted to short-termism, are bound to respond to ever-higher treatment prices with ever-higher copays, severely limiting access to expensive new drugs. How many people can afford a $1 million copay? Why would anyone in the pharmaceutical and biotechnology industries welcome such a future? Nations with cradle-to-grave insurance systems will be able to take advantage of the discoveries not only to rescue and improve lives but to capture savings, widening between the United States and other industrialized countries. Medicare for all may not be the only solution for the worsening short-termism of employer-based health care. If health insurers are faced with a rational long-term government alternative, they may respond competitively with their own long-term insurance products. Perhaps they could sell separate policies for genetic treatments. As the popularity of Medicare Advantage plans demonstrates, lifelong insurance guarantees need not be wholly government administered. Whatever the solution, science will soon offer the chance to glimpse and change our distant health futures. We will need a payment system that encourages such foresight. Rather than oppose every Medicare for all proposal, the pharmaceutical and biotechnology industries must help guide Washington toward a future made inevitable by their own astonishing discoveries.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Galvani, et.al., 2020 Alison P. Galvani, PhD,1,* Alyssa S. Parpia, MPH,1 Eric M. Foster,1 Burton H. Singer, PhD,2 and Meagan C. Fitzpatrick, PhD1,3Lancet. 2020 Feb 15; 395(10223): 524–533. Improving the Prognosis of Healthcare in the United States doi: 10.1016/S0140-6736(19)33019-3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572548/
Concerns have been expressed that reduced profits for pharmaceutical corporations would dampen biomedical innovation.50 However, the observed decline in scientific investmentwhich has accompanied consistently sizable profit margins for the pharmaceutical industry 52 suggests that the market assumptions underlying these concerns may be imperfect. Nonetheless, given that optimal or achievable prices might be different from those negotiated by the VA, our interactive tool allows the price reduction to vary from 0 to 60%. Even if pharmaceutical prices remained unaffected, the MAA would still reduce overall healthcare system costs (Figure 2).
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Link Turns/Defense
Andrea Fox 5-3-2017. (Andrea Fox is Editor of EfficientGov.com and Senior Editor at Praetorian Digital. She is based in Massachusetts. EfficientGov is an independent, unbiased information service providing innovative solutions to fiscal and operational challenges facing cities and towns around the world. Learn how we're helping local governments move forward, Andrea Fox. "Are We Really Back to 'National Healthcare versus Medical Innovation?'." EfficientGov. Web. 5-3-2017. accessed 9-11-2017. < https://efficientgov.com/blog/2017/05/03/national-healthcare-versus-medical-innovation/ >. Phops)
But a decade ago, the New Republic covered this very argument. Many disagree with the logic that higher healthcare costs kill the promise of innovative medical research. But it’s one thing to say that universal coverage could lead to less innovation or reduce the availability of high-tech care. It is quite another to say that it will do those things, which is the claim that opponents frequently make. That argument requires several leaps of logic, many of them highly suspect. The forces that produce innovation in medicine turn out to be a great deal more complicated than critics of universal coverage seem to grasp. Ultimately, whether innovation would continue to thrive under universal health care depends entirely on what kind of system we create and how well we run it. In fact, it’s quite possible that universal coverage could lead to better innovation,” wrote author Jonathan Cohn. He cited the National Institutes of Health as a key driver of medical innovation. Congress must agree with that because now — about 10 years later — they acted to increase NIH funding by $2 billion. Despite the fact that the proposed Trump budget called for a 20 percent slash to NIH. Don McCanne, MD’s comment — whenever he may have made it in the last decade — sums it up best, “The fundamental flaw in the argument that optimal innovation is possible only in a privately financed health system is the presumption that the quest for profit – the high profits characteristic of Wall Street supported firms – is the primary driving force behind innovation.” Governments — not just the private sector alone — can of course spawn, nurture and drive innovation. They can do things like: Find the key to a sickle cell cure (2009) Discover a genetic disorder causing strokes and vascular inflammation in children (2014) Target an antibody that stops the AIDS HIV virus from infecting a cell (2016)
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Uniqueness – BioPharma collapsing now
January 30, 2023 Decline of novel drug approvals means less business for cutting-edge CMOs https://www.pharmaceutical-technology.com/comment/decline-of-novel-drug-approvals/
The FDA approved fewer innovative drugs, New Molecular Entities (NMEs), in 2022 than it did in 2021: only 42 drugs compared to 59 drugs. This is due to generally more stringent criteria on approvals in the wake of the Aduhelm scandal. However, non-NME and biosimilar approvals increased in 2022. This is mixed news for contract manufacturing organisations (CMOs), as large CMOs such as (Waltham, MA, US) and Inc (Somerset, NJ, US) are typically involved in the manufacture of the most innovative products. In 2023, there will be opportunities for a wider range of CMOs that can offer services for less innovative drugs requiring reformulation or biosimilar production. Increased reluctance to authorise innovative and unproven drugs for use, stemming from the FDA’s experience with Aduhelm, reduced the overall novel approvals in 2022. In June 2021, the FDA granted accelerated approval of ’s (Cambridge, MA, US) Aduhelm (aducanumab-avwa) for Alzheimer’s disease, despite there being questionable evidence of clinical benefit and the majority of an FDA advisory panel voting against the drug’s approval. The approval was based on claims that the drug led to a reduction in amyloid plaques in the brain. However, Alzheimer’s disease is a complex illness, and its cause and pathophysiology are poorly understood. Aduhelm is both costly and commonly produces side effects.
2023
SDI
Affirmative
MSDI – Medicare for All Affirmative › 2AC --- Innovation DA › Uniqueness – BioPharma collapsing now
Deloitte pharma study: Drop-off in returns on R&D investments – sharp decline in peak sales per asset Zurich/Geneva, 23 January 2023 https://www2.deloitte.com/ch/en/pages/press-releases/articles/deloitte-pharma-study-drop-off-in-returns-on-r-and-d-investments-sharp-decline-in-peak-sales-per-asset.html
Here are the key findings: The top 20 global pharmaceutical companies collectively spent $139 billion on research and development in 2022, down two per cent from 2021. The average projected return on investment (ROI) from research and development fell to 1.2 per cent in 2022, its lowest level since the study was launched in 2010. The average development time for a new drug (from starting clinical trials to approval) increased from 6.9 years in 2021 to 7.1 years, the second longest since the study began. Due to the longer development times, the average cost of developing a new drug rose by $298 million to $2.3 billion in 2022. Average forecast peak sales per asset stood at $389 million in 2022, down from $500 million in 2021. The proportion of forecast revenue from assets co-developed by several companies more than halved year-on-year, falling from 46 per cent in 2021 to just 18 per cent in 2022. Thoughts on the findings and the Swiss pharmaceutical industry: “A decrease in returns from R&D investments was unavoidable in 2021, an unprecedented year marked by the COVID pandemic. However, no one expected the drop-off to be quite so severe. Even without the COVID-19 vaccines and treatments, ROI was still twice as high in 2021 as in 2022,” explains Nico Kleyn, Managing Partner Life Sciences and Health Care for Switzerland and North and South Europe (NSE). “Our analysis shows that the development of new treatments is taking longer and is costing more, and that they are generating less revenue. The research departments of pharmaceutical companies therefore need to transform the clinical trials process,” explains Alexander Mirow, partner and Consulting Industry Lead for Life Sciences at Deloitte Switzerland.